ASCO 2024 preview – two strikes against USP1
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
Erasca doubles down on RAS
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
ESMO Breast Cancer 2024 – Olema digs deep to declare victory
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
Calliditas puts a brave face on setanaxib failure
A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.
Glycomimetics down and out on upro miss
The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.
BridgeBio’s oncology spinout must stand out from the crowd
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
A Calquence win seven years in the making
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
